<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Virchows Arch</journal-id>
      <journal-title>Virchows Archiv</journal-title>
      <issn pub-type="ppub">0945-6317</issn>
      <issn pub-type="epub">1432-2307</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18266006</article-id>
      <article-id pub-id-type="pmc">2329735</article-id>
      <article-id pub-id-type="publisher-id">572</article-id>
      <article-id pub-id-type="doi">10.1007/s00428-007-0572-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Zheng</surname>
            <given-names>Hua-chuan</given-names>
          </name>
          <address>
            <email>zheng_huachuan@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Li</surname>
            <given-names>Xiao-han</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hara</surname>
            <given-names>Takuo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Masuda</surname>
            <given-names>Shinji</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yang</surname>
            <given-names>Xiang-hong</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Guan</surname>
            <given-names>Yi-fu</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Takano</surname>
            <given-names>Yasuo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang, China </aff>
        <aff id="Aff2"><label>2</label>Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan </aff>
        <aff id="Aff3"><label>3</label>Kouseiren Takaoka Hospital, Takaoka, Japan </aff>
        <aff id="Aff4"><label>4</label>Division of Pathology, Shengjing Hospital of China Medical University, Shenyang, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2008</year>
      </pub-date>
      <volume>452</volume>
      <issue>5</issue>
      <fpage>525</fpage>
      <lpage>534</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>11</month>
          <year>2007</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>12</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>12</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2008</copyright-statement>
      </permissions>
      <abstract>
        <p>To investigate the pathobiological behaviors of gastric mixed-type (MT) carcinomas and gastric carcinogenesis, the clinicopathological characteristics of MT carcinomas were analyzed and compared with intestinal-type (IT) and diffuse-type (DT) carcinomas. The expression of Ki-67, caspase-3, p53, fragile histine triad (FHIT), maspin, extracellular matrix metalloproteinase inducer (EMMPRIN), vascular growth factor (VEGF), MUC-2, 4, 5AC and 6, CD44, E-cadherin, &#x3B2;-catenin, and phosphorylated glycogen synthase kinase 3&#x3B2;-ser<sup>9</sup> (P-GSK3&#x3B2;-ser<sup>9</sup>) was examined on tissue microarrays using immunohistochemistry. It was found that MT carcinomas exhibited large size, deep invasion, frequent local invasion, and lymph node metastasis in comparison with IT and DT carcinomas (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). All the markers except MUC-5AC showed higher expression in IT than DT carcinomas (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). The expression of maspin, EMMPRIN, VEGF, MUC-4, and membrane E-cadherin was stronger in MT intestinal than diffuse component (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). Immunoreactivities to Ki-67, EMMPRIN, and VEGF were weaker in IT carcinoma than in the MT intestinal portion (<italic>p</italic>&#x2009;&lt;&#x2009;0.05), while the opposite was true for CD44, MUC-2, and MUC-6 (<italic>p&#x2009;</italic>&lt;&#x2009;0.05). The MT diffuse component displayed a higher expression of FHIT, VEGF, and P-GSK3&#x3B2;-ser<sup>9</sup> than DT carcinoma (<italic>p&#x2009;</italic>&lt;&#x2009;0.05). The accumulative survival rate of the IT carcinoma patients was higher than the other types (<italic>p&#x2009;</italic>&lt;&#x2009;0.05). The invasive depth, venous invasion, lymph node, peritoneal or liver metastasis, and Lauren's classification were independent prognostic factors for gastric carcinomas (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). These findings suggested that MT carcinomas were also indicated to be more aggressive than IT and DT carcinomas. Significant differences were observed in the proliferation, apoptosis, angiogenesis, mucin secretion, and cell adhesion between IT and DT carcinomas, whereas only a few of these characteristics showed differences between the MT intestinal and diffuse parts, thus suggesting that both the MT components might originate from the stem cells with similar genetic traits, but follow different histogenic pathways.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Gastric carcinoma</kwd>
        <kwd>Mixed type</kwd>
        <kwd>Lauren's classification</kwd>
        <kwd>Pathobiological behaviors</kwd>
        <kwd>Carcinogenesis</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2008</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Gastric carcinoma is the second leading cause of cancer-related death behind lung carcinoma despite a worldwide decline in both its incidence and mortality since the late half of the twentieth century [<xref ref-type="bibr" rid="CR11">11</xref>]. It continues to be a major health problem because of the slow decrease in incidence in Asia and high mortality of diagnosed gastric carcinoma in the West [<xref ref-type="bibr" rid="CR23">23</xref>]. Generally, the prognosis of patients with gastric carcinoma is somewhat dependent on its histological type, such as intestinal type (IT) or diffuse type (DT) as defined by Lauren [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
      <p>Although gastric carcinoma is a malignant tumor originating from the same gastric epithelium, its morphological features vary substantially among individual patients. Histologically, IT carcinoma principally includes papillary, well-differentiated, and moderately-differentiated or mucinous adenocarcinoma without signet ring carcinoma (SRC) cells, whereas DT mainly consists of the SRC, poorly differentiated and undifferentiated adenocarcinoma of WHO classification [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Although Kushima and Hattori [<xref ref-type="bibr" rid="CR12">12</xref>] firstly proposed an entity of gastric-type carcinoma and terminologically seemed homologous to the IT one, the carcinoma cells of this type closely resemble normal foveolar cells on the basis of tissue morphology and mucin properties and are considered to have been derived from foveolar hyperplasia or pyloric gland adenoma [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Recently, our group also focused on Lauren's classification and found that IT carcinoma frequently occurred in old men, while DT was more frequent in comparatively young women. The latter group was more inclined to invasion into the muscularis propria, lymphatic invasion, and lymph node metastasis, and belonged to a higher TNM staging, in comparison to its IT counterparts. Further analysis demonstrated that IT gastric carcinomas with a more favorable prognosis were prone to high levels of proliferation and apoptosis and also always accompanied by a strong expression of the fragile histine triad (FHIT), phosphatase and tensin homology deleted from human chromosome 10 (PTEN), p53, and extracellular matrix metalloproteinase inducer (EMMPRIN) [<xref ref-type="bibr" rid="CR30">30</xref>]. Additionally, many genetic and epigenetic changes, such as mutation, deletion, loss of heterozygosity, methylation, and microsatellite instability were differentially observed in both histological types of gastric carcinoma [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. These data indicate that different carcinogenic pathways exist for gastric IT and DT carcinomas. Although carcinogenesis is a multistage process which consists of a multi-factorial etiology resulting from gene&#x2013;environment interaction, the intestinal type is frequently related to environmental factors like diet and predominates in areas with a high incidence of this disease. In contrast, the diffuse type is thought to be of genetic origin and evenly distributed worldwide [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. It is commonly believed that Lauren's classification is valuable for both the epidemiological studies and gastric carcinogenesis.</p>
      <p>However, a small number of gastric carcinomas remain characterized as unclassified or mixed-type (MT) ones, which are comprised histologically of non-homogenous mixtures of IT and DT carcinomas. Stelzner and Emmrich [<xref ref-type="bibr" rid="CR26">26</xref>] found that 28 MT carcinomas showed a deep infiltration of the gastric wall, frequent regional lymph node metastasis, and high staging in comparison to the other two types. Machado et al. [<xref ref-type="bibr" rid="CR21">21</xref>] reported that inactivating E-cadherin mutations were exclusively observed in the diffuse component of the tumors, thus suggesting that MT carcinomas displayed phenotypic divergence. A recent study showed that bone-marrow-derived cells (BMDCs) could progress through metaplasia and dysplasia to intraepithelial cancer under the induction of the carcinogen, <italic>Helicobacter pylori</italic> [<xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, the analysis of distinct MT carcinoma components can be of remarkable pathogenic significance if it would be true that carcinoma cells originate from BMDCs. In the present study, 814 cases of gastric carcinomas were collected to further clarify the pathological characteristics of MT carcinoma and the gastric carcinogenesis pathways using a combination of tissue microarray (TMA) and immunohistochemical techniques.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Subjects</title>
        <p>A total of 814 gastric carcinomas were collected from surgical resection in Kouseiren Takaoka Hospital between 1998 and 2006. The patients with carcinomas included 573 men and 241 women (29&#x2013;91&#xA0;years, mean&#x2009;=&#x2009;65.7&#xA0;years). Among them, 312 cases were demonstrated with lymph node metastasis and 24 with liver metastasis. None of these cases underwent either chemotherapy or radiotherapy before surgery. All patients gave their informed consent for the use of tumor tissue specimens for clinical research and the University Ethical Committee approved the research protocol. All patients were followed up by consulting their case documents and through telephone interviews.</p>
      </sec>
      <sec id="Sec4">
        <title>Pathology</title>
        <p>All tissue specimens were fixed in 4% neutralized formaldehyde, embedded in paraffin, and cut into 4-&#x3BC;m sections. These sections were stained by hematoxylin and eosin (HE) to confirm their histological diagnosis and other microscopic characteristics. The staging for each gastric carcinoma was evaluated according to the TNM system of the Internationale Contre le Cancer (UICC) indicating the extent of tumor spread [<xref ref-type="bibr" rid="CR25">25</xref>]. The histomorphological architecture of the tumors was expressed according to Lauren's classification [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The growth patterns were divided into five groups based on a modification of Emmrich's method [<xref ref-type="bibr" rid="CR26">26</xref>]. Briefly, group I showed a combination of two components with diffuse distribution. Group II displayed both components with the border clearly visible. Group III represented some signet cells in the intestinal and diffuse components. Group IV were mucinous carcinomas with signet cells. Group V exhibited separately intestinal and diffuse components in the gastric wall. In addition, the depth of invasion, lymphatic and venous invasion, and peritoneal dissemination were all determined.</p>
      </sec>
      <sec id="Sec5">
        <title>Tissue microarray</title>
        <p>IT and DT carcinomas, as well as both components of the mixed type, were identified in HE stained sections of the selected tumor cases and a 2-mm-diameter tissue core of each donor block was punched out and transferred to a recipient block with a maximum of 48 cores using a Tissue Microarrayer (AZUMAYA KIN-1, Tokyo, Japan). Four-micrometer-thick sections were cut from the recipient block and transferred to poly-lysine-coated glass slides. HE staining was performed on TMA for confirmation of the tumor tissue (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>HE staining of TMA of gastric carcinomas</p></caption><graphic position="anchor" xlink:href="428_2007_572_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec6">
        <title>Immunohistochemistry</title>
        <p>Consecutive sections were deparaffinized with xylene, dehydrated with alcohol, and subjected to antigen retrieval by irradiating in target retrieval solution (TRS, DAKO, Carpinteria, UAS) for 15&#xA0;min in a microwave oven (Oriental rotor Lmt. Co. Tokyo, Japan). Five percent bovine serum albumin (BSA) was then applied for 15&#xA0;min to prevent non-specific binding. The sections were incubated with primary antibodies for 15&#xA0;min, then treated with the anti-mouse or anti-rabbit Envison-PO (DAKO, USA) antibodies for 15&#xA0;min. All incubations were performed in the microwave oven for intermittent irradiation as described previously [<xref ref-type="bibr" rid="CR15">15</xref>]. After each treatment, the slides were washed with TBST (10&#xA0;mM Tris&#x2013;HCl, 150&#xA0;mM NaCl, 0.1% Tween 20) three times for 1&#xA0;min. The primary antibodies are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. All immunostaining was visualized with 3, 3&#x2032;-diaminobenzidine (DAB) with 5-min reaction and counterstained with Mayer's hematoxylin. Omission of the primary antibody was used as a negative control.
<table-wrap id="Tab1"><caption><p>Table&#xA0;1 Primary antibodies used in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Names</th><th>Source</th><th>Company</th><th>Dilution</th></tr></thead><tbody><tr><td>Ki-67</td><td>Rabbit</td><td>DAKO, Carpinteria, USA</td><td>1:25</td></tr><tr><td>Caspase-3</td><td>Rabbit</td><td>DAKO, USA</td><td>1:150</td></tr><tr><td>p53</td><td>Mouse</td><td>DAKO, USA</td><td>1:100</td></tr><tr><td>FHIT</td><td>Rabbit</td><td>Neomarkers, Fremont, USA</td><td>1:200</td></tr><tr><td>Maspin</td><td>Mouse</td><td>Novocastra, Newcastle upon Tyne, UK</td><td>Read-to-use</td></tr><tr><td>EMMPRIN</td><td>Mouse</td><td>Novocastra, UK</td><td>1:100</td></tr><tr><td>VEGF</td><td>Rabbit</td><td>Labvision, Fremont, USA</td><td>1:50</td></tr><tr><td>P-GSK3&#x3B2;-ser<sup>9</sup></td><td>Rabbit</td><td>SAT, USA</td><td>1:300</td></tr><tr><td>MUC-2</td><td>Mouse</td><td>Novocastra, UK</td><td>1:100</td></tr><tr><td>MUC-4</td><td>Mouse</td><td>Novocastra, UK</td><td>1:100</td></tr><tr><td>MUC-5AC</td><td>Mouse</td><td>Novocastra, UK</td><td>1:100</td></tr><tr><td>MUC-6</td><td>Mouse</td><td>Novocastra, UK</td><td>1:100</td></tr><tr><td>CD44</td><td>Mouse</td><td>DAKO, USA</td><td>1:50</td></tr><tr><td>E-cadherin</td><td>Mouse</td><td>Takara, Otsu, Japan</td><td>1:100</td></tr><tr><td>&#x3B2;-Catenin</td><td>Mouse</td><td>Calbiochem, CA, USA</td><td>1:200</td></tr></tbody></table></table-wrap></p>
        <p>The immunoreactivity to Ki-67 and p53 was localized in the nucleus; FHIT, caspase-3, vascular growth factor (VEGF), maspin, phosphorylated glycogen synthase kinase 3&#x3B2;-ser<sup>9</sup> (P-GSK3&#x3B2;-ser<sup>9</sup>), MUC-2, MUC-5AC, and MUC-6 in the cytoplasm; EMMPRIN and MUC-4 in the cytoplasm and membrane; CD44 and E-cadherin in the membrane; and &#x3B2;-catenin in the nucleus, cytoplasm, and membrane (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). All evaluations were performed blindly by two independent observers (Takano Y and Zheng HC).
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Immunostaining of TMA of gastric carcinomas. The immunoreactivity to Ki-67 (<bold>a</bold>) and p53 (<bold>c</bold>) was localized in the nucleus; FHIT (<bold>d</bold>), caspase-3 (<bold>b</bold>), VEGF (<bold>g</bold>), maspin (<bold>e</bold>), P-GSK3&#x3B2;-ser<sup>9</sup> (<bold>h</bold>), MUC-2 (<bold>i</bold>), MUC-5AC (<bold>k</bold>), MUC-6 (<bold>l</bold>) were seen in the cytoplasm, EMMPRIN (<bold>f</bold>) and MUC-4 (<bold>j</bold>) were seen in the cytoplasm and the plasma membrane, CD44 (<bold>m</bold>), and E-cadherin (<bold>n</bold>) in the plasma membrane; and &#x3B2;-catenin (<bold>o</bold>) in the nucleus, cytoplasm, and plasma membrane. These molecules were strongly expressed in the intestinal-type gastric carcinomas</p></caption><graphic position="anchor" xlink:href="428_2007_572_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec7">
        <title>Statistical analysis</title>
        <p>The statistical evaluation was performed using Fisher's exact possibility to differentiate the rates and the Mann&#x2013;Whitney <italic>U</italic> test to differentiate the means of the different groups. Kaplan&#x2013;Meier survival plots were generated and comparisons between the survival curves were made with the log-rank statistic. The Cox proportional hazards model was employed for multivariate analysis. <italic>p</italic>&#x2009;&lt;&#x2009;0.05 was considered to represent a statistically significant difference. The SPSS 10.0 software program was employed to analyze all data.</p>
      </sec>
    </sec>
    <sec id="Sec8" sec-type="results">
      <title>Results</title>
      <sec id="Sec9">
        <title>Clinicopathological characteristics of gastric IT, DT, and MT carcinomas</title>
        <p>As summarized in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>, 415 IT cases were identified (51.0%), 221 DT (27.1%), and 178 MT (21.9%) among the 814 gastric carcinomas in this study. Patients with IT carcinoma were found to be significantly older than those with DT (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). The male and female ratios in the carcinoma cases gradually decreased from IT to DT through the MT groups (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). It was the same for lower TNM staging in the three groups (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). The positive rate of peritoneal spread was higher in the DT and MT cases than IT (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). MT carcinomas showed aggressive characteristics, such as large size, deep invasion, frequent local invasion, and lymph node metastasis, compared to the IT and DT (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). There was no significance between the three types of gastric carcinomas in the incidence of the liver metastasis (<italic>p</italic>&#x2009;&gt;&#x2009;0.05).
<table-wrap id="Tab2"><caption><p>Table&#xA0;2 Comparison of the clinicopathological features in gastric IT, DT, and MT carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinicopathological features</th><th>Intestinal-type carcinoma</th><th>Diffuse-type carcinoma</th><th>Mixed-type carcinoma</th></tr></thead><tbody><tr><td>Case number</td><td>415 (51.0%)</td><td>221 (27.1%)</td><td>178 (21.9%)</td></tr><tr><td>Age (mean &#xB1; SD, years)</td><td>67.09&#x2009;&#xB1;&#x2009;10.73</td><td>62.03&#x2009;&#xB1;&#x2009;11.3*</td><td>65.80&#x2009;&#xB1;&#x2009;13.28</td></tr><tr><td>Sex (male:female)</td><td>324:91</td><td>125:96</td><td>124:54**</td></tr><tr><td>Tumor size (mean &#xB1; SD, cm)</td><td>3.82&#x2009;&#xB1;&#x2009;3.21</td><td>5.50&#x2009;&#xB1;&#x2009;6.95</td><td>5.56&#x2009;&#xB1;&#x2009;3.08**</td></tr><tr><td>Invasion into muscularis propria</td><td>153 (36.9%)</td><td>121 (54.8%)</td><td>123 (69.1%)**</td></tr><tr><td>Lymphatic invasion (+)</td><td>117 (28.2%)</td><td>83 (37.6%)</td><td>99 (55.6%)**</td></tr><tr><td>Venous invasion (+)</td><td>49 (11.8%)</td><td>32 (14.5%)</td><td>39 (21.9%)**</td></tr><tr><td>Lymph node metastasis (+)</td><td>113 (27.2%)</td><td>94 (42.5%)</td><td>105 (59.0%)**</td></tr><tr><td>Liver metastasis (+)</td><td>10 (2.4%)</td><td>8 (3.6%)</td><td>6 (3.4%)</td></tr><tr><td>Peritoneal spread (+)</td><td>14 (3.4%)***</td><td>22 (10.0%)</td><td>21 (11.8%)</td></tr><tr><td>TNM staging (O, I)</td><td>302 (72.8%)</td><td>69 (31.2%)</td><td>112 (63.0%)**</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>&#x2009;&lt;&#x2009;0.05 compared with intestinal- and mixed-type carcinomas</p><p>**<italic>p</italic>&#x2009;&lt;&#x2009;0.05 compared with intestinal- and diffuse-type carcinomas with both analyzed</p><p>***<italic>p</italic>&#x2009;&lt;&#x2009;0.05 compared with diffuse- and mixed-type carcinomas</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec10">
        <title>Pathological behaviors of gastric MT carcinomas with different growth patterns or histological distribution of components</title>
        <p>According to the growth pattern, the intestinal and diffuse components diffusely distributed without absolute border in group I of the MT carcinomas, which occurred more frequently (60.0%, 106/178) than the other four groups. As indicated in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>, most groups III and V gastric carcinomas were generally of early stage with less local invasion, infrequent lymph node metastasis and low TNM staging. In this study, only four advanced gastric carcinomas belonged to group IV, among which three cases were women and all were accompanied with lymphangiogenic invasion, lymph node metastasis, and high TNM staging. Although the main histological component was different from that in lymph node metastasis, the statistical data revealed that there was histological consistency between primary and lymph node metastasis foci (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). There were no remarkable differences in the pathological behaviors of MT carcinomas with different ratios of intestinal and diffuse portions (<italic>p</italic>&#x2009;&gt;&#x2009;0.05).
<table-wrap id="Tab3"><caption><p>Table&#xA0;3 Pathological behaviors of gastric MT carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Clinicopathological features</th><th rowspan="2"><italic>n</italic></th><th rowspan="2">Sex (male)</th><th rowspan="2">Invasion into MP</th><th rowspan="2">Lymphatic invasion</th><th rowspan="2">Venous invasion</th><th colspan="4">Lymph node metastasis</th><th>Staging</th></tr><tr><th><italic>n</italic></th><th>I&gt;D</th><th>I=D</th><th>I&lt;D</th><th>(O, I)</th></tr></thead><tbody><tr><td>Growth pattern</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#xA0;I</td><td char="." align="char">106</td><td char="(" align="char">73 (68.9%)</td><td char="(" align="char">82 (77.4%)</td><td char="(" align="char">64 (60.4%)</td><td char="(" align="char">26 (24.5%)</td><td char="(" align="char">69 (65.1%)</td><td char="." align="char">32</td><td char="." align="char">14</td><td char="." align="char">23</td><td char="(" align="char">35 (33.0%)</td></tr><tr><td>&#xA0;II</td><td char="." align="char">25</td><td char="(" align="char">18 (78.3%)</td><td char="(" align="char">21 (84.0%)</td><td char="(" align="char">16 (64.0%)</td><td char="(" align="char">7 (28.0%)</td><td char="(" align="char">16 (64.0%)</td><td char="." align="char">5</td><td char="." align="char">5</td><td char="." align="char">6</td><td char="(" align="char">7 (28.0%)</td></tr><tr><td>&#xA0;III</td><td char="." align="char">29</td><td char="(" align="char">22 (75.9%)</td><td char="(" align="char">11 (37.9%)</td><td char="(" align="char">9 (31.0%)</td><td char="(" align="char">3 (10.3%)</td><td char="(" align="char">10 (34.5%)</td><td char="." align="char">4</td><td char="." align="char">3</td><td char="." align="char">3</td><td char="(" align="char">18 (62.1%)</td></tr><tr><td>&#xA0;IV</td><td char="." align="char">4</td><td char="(" align="char">1 (25.0%)</td><td char="(" align="char">4 (100.0%)</td><td char="(" align="char">4 (100.0%)</td><td char="(" align="char">1 (25.0%)</td><td char="(" align="char">4 (100.0%)</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">2</td><td char="(" align="char">0 (0.0%)</td></tr><tr><td>&#xA0;V</td><td char="." align="char">14</td><td char="(" align="char">10 (71.4%)</td><td char="(" align="char">5 (35.7%)</td><td char="(" align="char">6 (42.9%)</td><td char="(" align="char">2 (14.3%)</td><td char="(" align="char">6 (42.9%)</td><td char="." align="char">2</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="(" align="char">9 (64.3%)</td></tr><tr><td>Histological appearance</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#xA0;Intestinal&gt;diffuse</td><td char="." align="char">80</td><td char="(" align="char">59 (73.8%)</td><td char="(" align="char">54 (67.5%)</td><td char="(" align="char">43 (53.8%)</td><td char="(" align="char">20 (25.0%)</td><td char="(" align="char">48 (60.0%)</td><td char="." align="char">30</td><td char="." align="char">8</td><td char="." align="char">10</td><td char="(" align="char">33 (41.3%)</td></tr><tr><td>&#xA0;Intestinal=diffuse</td><td char="." align="char">20</td><td char="(" align="char">15 (75.0%)</td><td char="(" align="char">12 (60.0%)</td><td char="(" align="char">9 (45.0%)</td><td char="(" align="char">5 (25.0%)</td><td char="(" align="char">10 (50.0%)</td><td char="." align="char">3</td><td char="." align="char">5</td><td char="." align="char">2</td><td char="(" align="char">8 (40.0%)</td></tr><tr><td>&#xA0;Intestinal&lt;diffuse</td><td char="." align="char">78</td><td char="(" align="char">50 (64.1%)</td><td char="(" align="char">57 (73.1%)</td><td char="(" align="char">47 (60.3%)</td><td char="(" align="char">14 (18.0%)</td><td char="(" align="char">47 (60.3%)</td><td char="." align="char">10</td><td char="." align="char">11</td><td char="." align="char">26</td><td char="(" align="char">28 (35.9%)</td></tr></tbody></table><table-wrap-foot><p><italic>MP</italic> Muscularis propria; in lymph node metastatic foci: <italic>I&gt;D</italic> intestinal&gt;diffuse, <italic>I&lt;D</italic> intestinal&lt;diffuse, <italic>I=D</italic> intestinal=diffuse</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec11">
        <title>Immunohistochemical analysis of intestinal or diffuse components from three types of gastric carcinomas</title>
        <p>Table&#xA0;<xref rid="Tab4" ref-type="table">4</xref> demonstrates that all the markers except MUC-5AC were expressed at higher levels in IT carcinomas than in MT ones (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). The expression of maspin, EMMPRIN, VEGF, MUC-4, and E-cadherin was stronger in the intestinal component of MT carcinomas than in their diffuse counterpart (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). Immunoreactivities to Ki-67, EMMPRIN, and VEGF were weaker in the intestinal-type carcinomas than in the intestinal component of the MT (<italic>p</italic>&#x2009;&lt;&#x2009;0.05), while it was the opposite for CD44, MUC-2, and MUC-6 (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). In contrast, the diffuse components of the MT carcinomas showed greater expression of Ki-67, FHIT, VEGF, and P-GSK3&#x3B2;-ser<sup>9</sup> than DT carcinomas (<italic>p</italic>&#x2009;&lt;&#x2009;0.05).
<table-wrap id="Tab4"><caption><p>Table&#xA0;4 Immunohistochemical analysis in gastric IT, DT, and MT carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Biological markers</th><th rowspan="2">Intestinal-type carcinoma</th><th colspan="2">Mixed-type carcinoma</th><th rowspan="2">Diffuse-type carcinoma</th></tr><tr><th>Intestinal part</th><th>Diffuse part</th></tr></thead><tbody><tr><td>Ki-67</td><td char="(" align="char">88/146 (60.3%)*<sup>,</sup>**</td><td char="(" align="char">81/110 (73.6%)</td><td char="(" align="char">78/110 (70.9%)*</td><td char="(" align="char">57/119 (47.9%)</td></tr><tr><td>Caspase-3</td><td char="(" align="char">84/152 (55.3%)*</td><td char="(" align="char">52/119 (43.7%)</td><td char="(" align="char">37/119 (31.1%)</td><td char="(" align="char">24/115 (20.9%)</td></tr><tr><td>p53</td><td char="(" align="char">76/151 (50.3%)*</td><td char="(" align="char">37/118 (31.4%)</td><td char="(" align="char">30/118 (25.4%)</td><td char="(" align="char">25/120 (20.8%)</td></tr><tr><td>FHIT</td><td char="(" align="char">90/150 (60.0%)*</td><td char="(" align="char">63/113 (55.8%)</td><td char="(" align="char">48/113 (42.5%)*</td><td char="(" align="char">27/116 (23.3%)</td></tr><tr><td>Maspin</td><td char="(" align="char">71/150 (47.3%)*</td><td char="(" align="char">55/112 (49.1%)***</td><td char="(" align="char">34/112 (30.4%)</td><td char="(" align="char">38/120 (31.7%)</td></tr><tr><td>EMMPRIN</td><td char="(" align="char">87/147 (59.2%)*<sup>,</sup>**</td><td char="(" align="char">77/112 (68.8%)***</td><td char="(" align="char">43/112 (38.4%)</td><td char="(" align="char">32/117 (26.5%)</td></tr><tr><td>VEGF</td><td char="(" align="char">95/151 (62.9%)*<sup>,</sup>**</td><td char="(" align="char">90/114 (78.9%)***</td><td char="(" align="char">61/114 (53.5%)*</td><td char="(" align="char">31/121 (25.6%)</td></tr><tr><td>P-GSK3&#x3B2;-ser<sup>9</sup></td><td char="(" align="char">88/144 (61.1%)*</td><td char="(" align="char">74/113 (65.5%)</td><td char="(" align="char">67/113 (59.3%)*</td><td char="(" align="char">48/116 (41.4%)</td></tr><tr><td>MUC-2</td><td char="(" align="char">55/145 (37.9%)*<sup>,</sup>**</td><td char="(" align="char">31/118 (26.3%)</td><td char="(" align="char">27/118 (22.9%)</td><td char="(" align="char">23/117 (19.7%)</td></tr><tr><td>MUC-4</td><td char="(" align="char">58/153 (37.9%)*</td><td char="(" align="char">39/118 (33.1%)***</td><td char="(" align="char">21/118 (17.8%)</td><td char="(" align="char">18/118 (15.3%)</td></tr><tr><td>MUC-5AC</td><td char="(" align="char">84/148 (56.8%)</td><td char="(" align="char">57/106 (53.8%)</td><td char="(" align="char">50/106 (47.2%)</td><td char="(" align="char">54/113 (47.8%)</td></tr><tr><td>MUC-6</td><td char="(" align="char">60/146 (41.1%)*<sup>,</sup>**</td><td char="(" align="char">26/117 (22.2%)</td><td char="(" align="char">18/117 (15.4%)</td><td char="(" align="char">9/123 (7.3%)</td></tr><tr><td>CD44</td><td char="(" align="char">64/152 (42.1%)*<sup>,</sup>**</td><td char="(" align="char">32/114 (28.1%)</td><td char="(" align="char">31/114 (27.2%)</td><td char="(" align="char">32/120 (26.7%)</td></tr><tr><td>E-cadherin</td><td char="(" align="char">91/142 (64.1%)*</td><td char="(" align="char">58/112 (51.8%)***</td><td char="(" align="char">38/112 (33.9%)</td><td char="(" align="char">43/119 (36.1%)</td></tr><tr><td>Membrane &#x3B2;-catenin</td><td char="(" align="char">57/144 (39.6%)*</td><td char="(" align="char">36/117 (30.8%)</td><td char="(" align="char">26/117 (22.2%)</td><td char="(" align="char">26/118 (22.0%)</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>&#x2009;&lt;&#x2009;0.05 compared with the diffuse-type carcinomas</p><p>**<italic>p</italic>&#x2009;&lt;&#x2009;0.05 compared with intestinal-part carcinomas</p><p>***<italic>p</italic>&#x2009;&lt;&#x2009;0.05 compared with diffuse-part carcinomas</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec12">
        <title>Patients' outcome with different gastric carcinomas</title>
        <p>Follow-up information for 500 carcinoma patients was used before 2002 for a period ranging from 5&#xA0;days to 9.15&#xA0;years (mean&#x2009;=&#x2009;49.4&#xA0;months). Figure <xref rid="Fig3" ref-type="fig">3</xref> shows the survival curves stratified according to Lauren's classification. Kaplan&#x2013;Meier analysis indicated that the patients with IT carcinoma had a higher cumulative survival rate than those with the DT and MT lesions (<italic>p</italic>&#x2009;&lt;&#x2009;0.05). Although the MT carcinoma patients' survival rate was comparatively lower than the DT ones, there was no statistical significance (<italic>p</italic>&#x2009;&gt;&#x2009;0.05). Multivariate analysis demonstrated that invasive depth, venous invasion, lymph node, peritoneal or liver metastasis, and Lauren's classification were independent factors for the poor prognosis of gastric carcinoma patients (<italic>p</italic>&#x2009;&lt;&#x2009;0.05; Table <xref rid="Tab5" ref-type="table">5</xref>).
<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Relationship between prognosis of carcinoma patients' and Lauren's classification Kaplan&#x2013;Meier curves of cumulative survival rate for the patients with gastric carcinoma according to Lauren's classification. <italic>IT</italic> Intestinal type, <italic>DT</italic> diffuse type, <italic>MT</italic> mixed type</p></caption><graphic position="anchor" xlink:href="428_2007_572_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab5"><caption><p>Table&#xA0;5 Multivariate analysis of the clinicopathological variables of gastric carcinomas</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinicopathological parameters</th><th>Relative risk (95% CI)</th><th><italic>p</italic> Value</th></tr></thead><tbody><tr><td>Age (&#x2265;65&#xA0;years)</td><td char="(" align="char">1.224 (0.849&#x2013;1.764)</td><td char="." align="char">&gt;0.05</td></tr><tr><td>Sex (male:female)</td><td char="(" align="char">1.255 (0.827&#x2013;1.904)</td><td char="." align="char">&gt;0.05</td></tr><tr><td>Tumor size (&#x2265;4&#xA0;cm)</td><td char="(" align="char">1.466 (0.862&#x2013;2.493)</td><td char="." align="char">&gt;0.05</td></tr><tr><td>Invasive depth (Ti<sub>s,1</sub>/<italic>T</italic><sub>2,3</sub>)</td><td char="(" align="char">2.945 (1.533&#x2013;5.657)</td><td char="." align="char">&lt;0.05</td></tr><tr><td>Lymphatic invasion (&#x2212;/+)</td><td char="(" align="char">1.394 (0.865&#x2013;2.247)</td><td char="." align="char">&gt;0.05</td></tr><tr><td>Venous invasion (&#x2212;/+)</td><td char="(" align="char">1.692 (1.097&#x2013;2.608)</td><td char="." align="char">&lt;0.05</td></tr><tr><td>Lymph node metastasis (&#x2212;/+)</td><td char="(" align="char">1.983 (1.111&#x2013;3.537)</td><td char="." align="char">&lt;0.05</td></tr><tr><td>Peritoneal spread (&#x2212;/+)</td><td char="(" align="char">3.197 (2.031&#x2013;5.031)</td><td char="." align="char">&lt;0.05</td></tr><tr><td>Liver metastasis (&#x2212;/+)</td><td char="(" align="char">5.248 (2.575&#x2013;10.697)</td><td char="." align="char">&lt;0.05</td></tr><tr><td>Lauren's classification (intestinal/diffuse/mixed)</td><td char="(" align="char">1.351 (1.084&#x2013;1.683)</td><td char="." align="char">&lt;0.05</td></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> Confidence interval</p></table-wrap-foot></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec13" sec-type="discussion">
      <title>Discussion</title>
      <p>Histologically, Lauren's classification of gastric carcinomas is based on the morphological appearances. IT carcinomas are characterized by cohesive carcinoma cells forming gland-like tubular structures with an expanding or infiltrative growth pattern, like a papillary and well-differentiated adenocarcinoma. However, the cell cohesion is less apparent or absent in DT carcinomas, and cancer cells diffusely spread in the gastric wall as poorly differentiated adenocarcinomas, SRC, or undifferentiated carcinomas [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, there are two types of histological distribution in the MT carcinoma, as described by Lauren [<xref ref-type="bibr" rid="CR16">16</xref>]. In this study, carcinoma diagnosed as MT made up 21.9% of the whole series in this population, more than that reported by Borch et al. (13%), Lauren (14%), and Stelzner and Emmrich (14.1%), and less than that reported by Carneiro et al. (38.5%) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. This discrepancy might be due to the differences in diagnosis criteria, geographical regions, human races, living habits, and so forth. The age and sex distribution of the patients with MT carcinoma was intermediate although IT carcinomas frequently occurred in old men, compared with DT carcinomas.</p>
      <p>Morphologically, there are both intestinal and diffuse components in MT carcinomas, and they were found to be significantly larger, more advanced, and more frequently spread into local lymphatic and venous vessels or regional lymph nodes, compared with IT and DT carcinomas in the present study, consistent with other reports [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Kozuki et al. [<xref ref-type="bibr" rid="CR14">14</xref>] found that prominent lymphatic permeation and lymph node metastasis were more frequently observed in MT than in the pure type of gastric carcinomas. It was previously documented that the MT carcinomas showed a deeper infiltration of the gastric wall, a higher metastatic rate to the regional lymph nodes, and the need for higher staging with the TNM system of UICC classification, in contrast to IT and MT carcinomas [<xref ref-type="bibr" rid="CR26">26</xref>]. These findings suggest that the pathobiological characteristics of the MT carcinomas were more aggressive than the other two types, which accounted for their comparatively poor prognosis observed in the present study although there was no statistical significance. Among the MT carcinomas, five groups were classified according to their growth pattern. Half of the present cases belonged to group I, which means there was diffuse distribution of the intestinal and diffuse component without clear borders in most of the MT cases. In general, groups III and IV of MT carcinomas did not exhibit deep invasion, comparatively high staging or frequent spreading, compared with other types. However, group IV of carcinomas with mucin and signet cells was more advanced with wide spreading, including local vessels and lymph node metastasis. Therefore, surgeons should carefully treat the patients with MT carcinomas in clinical practice because of their aggressive characteristics and poor prognosis, especially those classified as group IV. Furthermore, it was found that the major component in the MT primary foci morphologically paralleled to that in the corresponding lymph node metastasis although the converse situation also appeared. This inconsistent phenomenon could be explained by sampling bias or the metastatic potential of individual carcinoma cells.</p>
      <p>Compared with IT carcinomas, the MT counterpart always exhibited more severe characteristics, including invasion into muscularis propria, lymphatic invasion and lymph node metastasis, and high TNM staging in the present study, as observed by Lauren and other studies [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. To clarify the pheno/genotypes of gastric carcinoma, the expression of Ki-67, caspase-3, p53, FHIT, maspin, VEGF, EMMPRIN, P-GSK3&#x3B2;-ser<sup>9</sup>, MUC-2, MUC-4, MUC-5AC, MUC-6, E-cadherin, and &#x3B2;-catenin was examined by immunostaining. p53, FHIT, and maspin as tumor suppressor genes play important roles in regulating the balance between the proliferation and apoptosis of cancer cells [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Ki-67 antigen is present in the nuclei of cells undergoing proliferation and should be regarded as a good marker for cell proliferation [<xref ref-type="bibr" rid="CR34">34</xref>]. Caspase-3 is responsible for the cleavage of poly (ADP-ribose) polymerase, actin, and sterol regulatory element binding protein and reflects the apoptotic level as a key protease in the cascade reaction of the apoptotic pathway [<xref ref-type="bibr" rid="CR28">28</xref>]. In vivo and vitro evidences indicated that EMMPRIN and VEGF are involved in angiogenic processes in malignancies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Glycogen synthase kinase-3&#x3B2; (GSK3&#x3B2;) belongs to the serine/threonine protein kinase family and is also involved in regulating the balance between proliferation and apoptosis and can be inactivated via ser-9 phosphorylation by p70 S6 kinase, p90Rsk, Akt, certain isoforms of proteins kinase, and cyclic AMP-dependent protein kinase [<xref ref-type="bibr" rid="CR1">1</xref>]. MUC-2, MUC-5AC, and MUC-6 are markers for intestinal goblet cells, superficial epithelium, and gastric pyloric gland cells, respectively, which can reflect the mucin secretion and variations in gastrointestinal malignancies. MUC-4 is a heterodimeric glycoprotein complex and expressed in several human epithelial carcinomas [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. CD44 is a cell surface glycoprotein involved in cell/cell and cell/matrix interactions. CD44 overexpression has been linked to the growth and spread of a range of different types of malignancies [<xref ref-type="bibr" rid="CR8">8</xref>]. The E-cadherin can interact with &#x3B2;-catenin to form a complex, which is closely linked to cell adhesion and differentiation [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In the present study, all of the markers except MUC-5AC showed greater expression in the IT than in the DT carcinomas. Although some evidences indicate that MUC-5AC was strongly expressed in gastric DT carcinoma, in comparison with IT ones, there was no statistical difference in line with our finding [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. These data suggested that there were significant differences in the proliferation, apoptosis, angiogenesis, mucin production, and cell adhesion between the IT and DT carcinomas and these molecules mechanistically contributed to the molecular distinction in the morphological, behavioral, and histogenic aspects between both types of gastric carcinomas.</p>
      <p>In general, DT carcinoma is believed to derive de novo from the peripheral stem cells of gastric gland neck proliferative zone without a recognizable precursor lesion except hereditary diffuse gastric cancer because in situ carcinoma or globoid dysplasia is its precancerous lesion, respectively, according to the Chinese and Western pathologists' opinions [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR30">30</xref>]. When long-standing gastric inflammation causes tissue injury and stem cell failure with time, BMDCs are recruited and engrafted into the tissue stem cell niche, where BMDCs can behave in a way indistinguishable from endogenous tissue stem cells. With continued inflammation and injury, they can undergo sustained proliferation and malignant transformation into IT carcinomas, passing through precancerous stages of metaplasia and dysplasia when genetic defects, such as mutation, deletion, or rearrangement, are accumulated resulting in corruption of the balance between proliferation and apoptosis [<xref ref-type="bibr" rid="CR17">17</xref>]. Likewise, dedifferentiation of intestinal to diffuse carcinoma had been identified as another histogenic pathway according to the histological heterogeneity of tumor cells, especially in the carcinomas containing moderately and poorly differentiated components with similar morphological appearance and diffuse distribution. If so, it is possible that the distinct components in MT carcinomas arise from the stem cells with common genetic traits and follow different carcinogenic pathways. Conversely, diffuse carcinoma could be derived from heterogeneity of the intestinal counterpart. According to our present data, no differences in the expression of Ki-67, caspase-3, FHIT, CD44, P-GSK3&#x3B2;-ser<sup>9</sup>, MUC-2, MUC-5AC, MUC-6, and membrane &#x3B2;-catenin were observed between the intestinal and diffuse components of MT carcinomas, which supports the possibility of similar origin or dedifferentiation. However, increased expression of EMMPRIN, VEGF, MUC-4, and E-cadherin in the intestinal component compared to the diffuse counterpart also provided evidence that the original carcinoma cells might undergo distinct carcinogenic routes resulting in the morphological distinction of both components. Both the intestinal and diffuse components in MT carcinomas had increased expression of Ki-67, EMMPRIN, and VEGF and reduced E-cadherin. Serum VEGF levels were found to be significantly higher in patients with MT gastric carcinomas than those with pure lesions [<xref ref-type="bibr" rid="CR10">10</xref>]. It was proposed that MT carcinomas biologically displayed more aggressive behaviors than other types, including decreased cell adhesion, increased proliferation, and angiogenesis.</p>
      <p>Most of the evidences in the present data indicated that the pathological behaviors of MT carcinomas were more aggressive than the other types, which was closely linked to the prognosis. It was previously documented that the MT patients' survival is significantly worse than those with IT or DT carcinomas regardless of their location [<xref ref-type="bibr" rid="CR5">5</xref>]. However, this study demonstrated that there was no significance between the MT and DT carcinoma patients' survival rates although the former was lower than the latter. Additionally, both survival rates were lower than that with IT carcinomas. To avoid sampling bias from a shorter follow-up time, the older cases were chosen for the survival analysis, but they yielded consistent results. Furthermore, Cox's hazard proportional analysis indicated that the invasive depth, venous invasion, lymph node, peritoneal or liver metastasis, and Lauren's classification were independent prognostic factors for gastric carcinomas.</p>
      <p>In summary, IT carcinoma, which is positively correlated with favorable prognosis, frequently displayed high levels of proliferation, apoptosis, angiogenesis, mucin production, and cell adhesion. Gastric MT carcinoma showed more aggressive behaviors than IT and DT ones. There was a significant difference in the proliferation, apoptosis, angiogenesis, mucin secretion, and cell adhesion between the IT and DT carcinomas, whereas only a few characteristics were differentially detected in the intestinal and diffuse component of the mixed-type carcinoma, suggesting that different components of MT carcinoma might originate from common stem cells, but follow distinct histogenic pathways. Furthermore, these results confirm that Lauren's classification is significant regarding the histopathogenesis and differentiation and considered as a guide to the clinical treatment of gastric carcinoma.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We particularly thank Tokimasa Kumada and Hideki Hatta for their technical help and Yukari Inoue for her valuable secretarial assistance. This work was partially supported by the Japanese Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research 14770072, Japanese Smoking Foundation, Shenyang Outstanding Talent Foundation, and Natural Scientific Foundation of China (30600286).</p>
      <p><bold>Conflict of interest statement</bold> No conflict of interest.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ali</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hoeflich</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Woodgett</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Glycogen synthase kinase-3: properties, functions, and regulation</article-title>
          <source>Chem Rev</source>
          <year>2001</year>
          <volume>101</volume>
          <fpage>2527</fpage>
          <lpage>2540</lpage>
        </citation>
        <citation citation-type="display-unstructured">Ali A, Hoeflich KP, Woodgett JR (2001) Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 101:2527&#x2013;2540 <pub-id pub-id-type="pmid">11749387</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borch</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jonsson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tarpila</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Franzen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Berglund</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kullman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Franzen</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma</article-title>
          <source>Br J Surg</source>
          <year>2000</year>
          <volume>87</volume>
          <fpage>618</fpage>
          <lpage>626</lpage>
        </citation>
        <citation citation-type="display-unstructured">Borch K, Jonsson B, Tarpila E, Franzen T, Berglund J, Kullman E, Franzen L (2000) Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg 87:618&#x2013;626 <pub-id pub-id-type="pmid">10792320</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byrd</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bresalier</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Mucins and mucin binding proteins in colorectal cancer</article-title>
          <source>Cancer Metastasis Rev</source>
          <year>2004</year>
          <volume>23</volume>
          <fpage>77</fpage>
          <lpage>99</lpage>
        </citation>
        <citation citation-type="display-unstructured">Byrd JC, Bresalier RS (2004) Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 23:77&#x2013;99 <pub-id pub-id-type="pmid">15000151</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Huntsman</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Smyrk</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Owen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Seruca</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pharoah</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Caldas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sobrinho-Sim&#xF5;es</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening</article-title>
          <source>J Pathol</source>
          <year>2004</year>
          <volume>203</volume>
          <fpage>681</fpage>
          <lpage>687</lpage>
        </citation>
        <citation citation-type="display-unstructured">Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, Caldas C, Sobrinho-Sim&#xF5;es M (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681&#x2013;687 <pub-id pub-id-type="pmid">15141383</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Seixas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sobrinho-Simoes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>New elements for an updated classification of the carcinomas of the stomach</article-title>
          <source>Pathol Res Pract</source>
          <year>1995</year>
          <volume>191</volume>
          <fpage>571</fpage>
          <lpage>584</lpage>
        </citation>
        <citation citation-type="display-unstructured">Carneiro F, Seixas M, Sobrinho-Simoes M (1995) New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract 191:571&#x2013;584 <pub-id pub-id-type="pmid">7479380</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hirayama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hirokawa</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>A comparison of patterns of metastasis in gastric cancer by histologic type and age</article-title>
          <source>Cancer</source>
          <year>1990</year>
          <volume>65</volume>
          <fpage>2086</fpage>
          <lpage>2090</lpage>
        </citation>
        <citation citation-type="display-unstructured">Esaki Y, Hirayama R, Hirokawa K (1990) A comparison of patterns of metastasis in gastric cancer by histologic type and age. Cancer 65:2086&#x2013;2090 <pub-id pub-id-type="pmid">2372774</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="other">Hamilton SR, Aaltonen LA (eds) (2000) In: WHO classification of tumors: pathology and genetics of tumors of the digestive system. IARC, Lyon, pp 39&#x2013;50</citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hong</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Shun</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>YC</given-names>
            </name>
          </person-group>
          <article-title>Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas</article-title>
          <source>Oncology</source>
          <year>1995</year>
          <volume>52</volume>
          <fpage>334</fpage>
          <lpage>339</lpage>
        </citation>
        <citation citation-type="display-unstructured">Hong RL, Lee WJ, Shun CT, Chu JS, Chen YC (1995) Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastric adenocarcinomas. Oncology 52:334&#x2013;339 <pub-id pub-id-type="pmid">7539903</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houghton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stoicov</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nomura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Goldenring</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>Gastric cancer originating from bone marrow-derived cells</article-title>
          <source>Science</source>
          <year>2004</year>
          <volume>306</volume>
          <fpage>1568</fpage>
          <lpage>1571</lpage>
        </citation>
        <citation citation-type="display-unstructured">Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC (2004) Gastric cancer originating from bone marrow-derived cells. Science 306:1568&#x2013;1571 <pub-id pub-id-type="pmid">15567866</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>2002</year>
          <volume>17</volume>
          <fpage>1165</fpage>
          <lpage>1169</lpage>
        </citation>
        <citation citation-type="display-unstructured">Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML, Lin JT (2002) Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 17:1165&#x2013;1169 <pub-id pub-id-type="pmid">12453275</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelley</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Duggan</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Gastric cancer epidemiology and risk factors</article-title>
          <source>J Clin Epidemiol</source>
          <year>2003</year>
          <volume>56</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1&#x2013;9 <pub-id pub-id-type="pmid">12589864</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kushima</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hattori</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach</article-title>
          <source>J Cancer Res Clin Oncol</source>
          <year>1993</year>
          <volume>120</volume>
          <fpage>103</fpage>
          <lpage>111</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kushima R, Hattori T (1993) Histogenesis and characteristics of gastric-type adenocarcinomas in the stomach. J Cancer Res Clin Oncol 120:103&#x2013;111 <pub-id pub-id-type="pmid">7903667</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kushima</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Vieth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Borchard</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Stolte</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mukaisho</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hattori</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach</article-title>
          <source>Gastric Cancer</source>
          <year>2006</year>
          <volume>9</volume>
          <fpage>177</fpage>
          <lpage>184</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kushima R, Vieth M, Borchard F, Stolte M, Mukaisho K, Hattori T (2006) Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach. Gastric Cancer 9:177&#x2013;184 <pub-id pub-id-type="pmid">16952035</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kozuki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsuneyoshi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Differences in p53 and cadherin&#x2013;catenin complex expression between histological subtypes in diffusely infiltrating gastric carcinoma</article-title>
          <source>Histopathology</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>56</fpage>
          <lpage>64</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kozuki T, Yao T, Nakamura S, Matsumoto T, Tsuneyoshi M (2002) Differences in p53 and cadherin&#x2013;catenin complex expression between histological subtypes in diffusely infiltrating gastric carcinoma. Histopathology 41:56&#x2013;64 <pub-id pub-id-type="pmid">12121238</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hatta</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ishizawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital</article-title>
          <source>Mod Pathol</source>
          <year>2004</year>
          <volume>17</volume>
          <fpage>1141</fpage>
          <lpage>1149</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y (2004) Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 17:1141&#x2013;1149 <pub-id pub-id-type="pmid">15167936</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lauren</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification</article-title>
          <source>Acta Pathol Microbiol Scand</source>
          <year>1965</year>
          <volume>64</volume>
          <fpage>31</fpage>
          <lpage>49</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31&#x2013;49 <pub-id pub-id-type="pmid">14320675</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Stoicov</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Houghton</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers</article-title>
          <source>World J Gastroenterol</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>363</fpage>
          <lpage>371</lpage>
        </citation>
        <citation citation-type="display-unstructured">Li HC, Stoicov C, Rogers AB, Houghton J (2006) Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. World J Gastroenterol 12:363&#x2013;371 <pub-id pub-id-type="pmid">16489634</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
          <article-title>A newly recognized precancerous lesion of the stomach&#x2014;histopathologic features of globoid dysplasia of human gastric epithelium</article-title>
          <source>Zhonghua Zhong Liu Za Zhi</source>
          <year>1989</year>
          <volume>11</volume>
          <fpage>37</fpage>
          <lpage>40</lpage>
        </citation>
        <citation citation-type="display-unstructured">Liu SC (1989) A newly recognized precancerous lesion of the stomach&#x2014;histopathologic features of globoid dysplasia of human gastric epithelium. Zhonghua Zhong Liu Za Zhi 11:37&#x2013;40 <pub-id pub-id-type="pmid">2550197</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Grady</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Suriano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Huntsman</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Gastric cancer: new genetic developments</article-title>
          <source>J Surg Oncol</source>
          <year>2005</year>
          <volume>90</volume>
          <fpage>114</fpage>
          <lpage>133</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic developments. J Surg Oncol 90:114&#x2013;133 <pub-id pub-id-type="pmid">15895459</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machado</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Sobrinho-Sim&#xF5;es</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Gastric carcinoma exhibits distinct types of cell differentiation: an immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6)</article-title>
          <source>J Pathol</source>
          <year>2000</year>
          <volume>190</volume>
          <fpage>437</fpage>
          <lpage>43</lpage>
        </citation>
        <citation citation-type="display-unstructured">Machado JC, Nogueira AM, Carneiro F, Reis CA, Sobrinho-Sim&#xF5;es M (2000) Gastric carcinoma exhibits distinct types of cell differentiation: an immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6). J Pathol 190:437&#x2013;43 <pub-id pub-id-type="pmid">10699992</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machado</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blin</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Berx</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sobrinho-Simoes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas</article-title>
          <source>Lab Invest</source>
          <year>1999</year>
          <volume>79</volume>
          <fpage>459</fpage>
          <lpage>465</lpage>
        </citation>
        <citation citation-type="display-unstructured">Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G, Sobrinho-Simoes M (1999) E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 79:459&#x2013;465 <pub-id pub-id-type="pmid">10211998</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reis</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Clausen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mirgorodskaya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Roepstorff</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sobrinho-Sim&#xF5;es</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody</article-title>
          <source>Int J Cancer</source>
          <year>1997</year>
          <volume>74</volume>
          <fpage>112</fpage>
          <lpage>121</lpage>
        </citation>
        <citation citation-type="display-unstructured">Reis CA, David L, Nielsen PA, Clausen H, Mirgorodskaya K, Roepstorff P, Sobrinho-Sim&#xF5;es M (1997) Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int J Cancer 74:112&#x2013;121 <pub-id pub-id-type="pmid">9036879</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roukos</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Agnantis</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Fatouros</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kappas</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Gastric cancer: introduction, pathology, epidemiology</article-title>
          <source>Gastric &amp; Breast Cancer</source>
          <year>2002</year>
          <volume>1</volume>
          <fpage>1</fpage>
          <lpage>3</lpage>
        </citation>
        <citation citation-type="display-unstructured">Roukos DH, Agnantis NJ, Fatouros M, Kappas AM (2002) Gastric cancer: introduction, pathology, epidemiology. Gastric &amp; Breast Cancer 1:1&#x2013;3 </citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shibata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Longacre</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Puligandla</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Parsonnet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Habel</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Histological classification of gastric adenocarcinoma for epidemiological research: concordance between pathologists</article-title>
          <source>Cancer Epidemiol Biomarkers Prev</source>
          <year>2001</year>
          <volume>10</volume>
          <fpage>75</fpage>
          <lpage>78</lpage>
        </citation>
        <citation citation-type="display-unstructured">Shibata A, Longacre TA, Puligandla B, Parsonnet J, Habel LA (2001) Histological classification of gastric adenocarcinoma for epidemiological research: concordance between pathologists. Cancer Epidemiol Biomarkers Prev 10:75&#x2013;78 <pub-id pub-id-type="pmid">11205493</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Sobin</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Wittekind</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <source>TNM classification of malignant tumors</source>
          <year>2002</year>
          <edition>6</edition>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>John Wiley</publisher-name>
          <fpage>55</fpage>
          <lpage>65</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sobin LH, Wittekind CH (2002) TNM classification of malignant tumors, 6th edn. John Wiley, New York, pp 55&#x2013;65 </citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stelzner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Emmrich</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The mixed type in Lauren's classification of gastric carcinoma. Histologic description and biologic behavior</article-title>
          <source>Gen Diagn Pathol</source>
          <year>1997</year>
          <volume>143</volume>
          <fpage>39</fpage>
          <lpage>48</lpage>
        </citation>
        <citation citation-type="display-unstructured">Stelzner S, Emmrich P (1997) The mixed type in Lauren's classification of gastric carcinoma. Histologic description and biologic behavior. Gen Diagn Pathol 143:39&#x2013;48 <pub-id pub-id-type="pmid">9269907</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tahara</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Genetic pathways of two types of gastric cancer</article-title>
          <source>IARC Sci Publ</source>
          <year>2004</year>
          <volume>157</volume>
          <fpage>327</fpage>
          <lpage>349</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157:327&#x2013;349 <pub-id pub-id-type="pmid">15055305</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>ZL</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>XF</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Xin</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer</article-title>
          <source>World J Gastroenterol</source>
          <year>2003</year>
          <volume>9</volume>
          <fpage>1415</fpage>
          <lpage>1420</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y (2003) Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol 9:1415&#x2013;1420 <pub-id pub-id-type="pmid">12854132</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Niwa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma</article-title>
          <source>Anticancer Res</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>3579</fpage>
          <lpage>3583</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K, Takano Y (2006a) Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 26:3579&#x2013;3583 <pub-id pub-id-type="pmid">17094486</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miwa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Pathobiological characteristics of intestinal- and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray</article-title>
          <source>J Clin Pathol</source>
          <year>2007</year>
          <volume>60</volume>
          <fpage>273</fpage>
          <lpage>277</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K, Takano Y (2007a) Pathobiological characteristics of intestinal- and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 60:273&#x2013;277 <pub-id pub-id-type="pmid">16714395</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Masuda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Low expression of FHIT and PTEN correlates with malignancy of gastric carcinoma: tissue-array findings</article-title>
          <source>Appl Immunohistochem Mol Morphol</source>
          <year>2007</year>
          <volume>15</volume>
          <issue>4</issue>
          <fpage>432</fpage>
          <lpage>440</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Tsuneyama K, Masuda S, Takano Y (2007b) Low expression of FHIT and PTEN correlates with malignancy of gastric carcinoma: tissue-array findings. Appl Immunohistochem Mol Morphol 15(4):432&#x2013;440 <pub-id pub-id-type="pmid">18091387</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Murai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>ZG</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miwa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis</article-title>
          <source>Br J Cancer</source>
          <year>2006</year>
          <volume>95</volume>
          <fpage>1371</fpage>
          <lpage>1378</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, Tsuneyama K, Takano Y (2006d) Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 95:1371&#x2013;1378 <pub-id pub-id-type="pmid">17088917</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Murai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>MUC6 down-regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays</article-title>
          <source>J Cancer Res Clin Oncol</source>
          <year>2006</year>
          <volume>132</volume>
          <fpage>817</fpage>
          <lpage>823</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng H, Takahashi H, Nakajima T, Murai Y, Cui Z, Nomoto K, Tsuneyama K, Takano Y (2006b) MUC6 down-regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays. J Cancer Res Clin Oncol 132:817&#x2013;823 <pub-id pub-id-type="pmid">16807756</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Murai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>An immunohistochemical study of p53 and Ki-67 in gastrointestinal adenoma and adenocarcinoma using tissue microarray</article-title>
          <source>Anticancer Res</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>2353</fpage>
          <lpage>2360</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K, Takano Y (2006c) An immunohistochemical study of p53 and Ki-67 in gastrointestinal adenoma and adenocarcinoma using tissue microarray. Anticancer Res 26:2353&#x2013;2360 <pub-id pub-id-type="pmid">16821616</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsuneyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Murai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nomoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Maspin expression was involved in colorectal adenoma&#x2013;adenocarcinoma sequence and liver metastasis of tumors</article-title>
          <source>Anticancer Res</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>259</fpage>
          <lpage>265</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, Nomoto K, Takano Y (2007c) Maspin expression was involved in colorectal adenoma&#x2013;adenocarcinoma sequence and liver metastasis of tumors. Anticancer Res 27:259&#x2013;265 <pub-id pub-id-type="pmid">17352241</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ajani</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis of gastric cancer development and progression</article-title>
          <source>Gastric Cancer</source>
          <year>2004</year>
          <volume>7</volume>
          <fpage>61</fpage>
          <lpage>77</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zheng L, Wang L, Ajani J, Xie K (2004) Molecular basis of gastric cancer development and progression. Gastric Cancer 7:61&#x2013;77 <pub-id pub-id-type="pmid">15224192</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>